Cargando…
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
CC-115, a selective dual inhibitor of the mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase (DNA-PK), is undergoing Phase 1 clinical studies. Here we report the characterization of DNA-PK inhibitory activity of CC-115 in cancer cell lines. CC-115 inhibits auto-phosphorylat...
Autores principales: | Tsuji, Toshiya, Sapinoso, Lisa M., Tran, Tam, Gaffney, Bonny, Wong, Lilly, Sankar, Sabita, Raymon, Heather K., Mortensen, Deborah S., Xu, Shuichan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650372/ https://www.ncbi.nlm.nih.gov/pubmed/29088817 http://dx.doi.org/10.18632/oncotarget.20342 |
Ejemplares similares
-
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
por: Munster, Pamela, et al.
Publicado: (2019) -
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
por: Bürkel, Felix, et al.
Publicado: (2020) -
An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth
por: Chen, Fagui, et al.
Publicado: (2022) -
Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth
por: Zheng, Bing, et al.
Publicado: (2020) -
Inhibition of DNA Repair by Inappropriate Activation of ATM, PARP, and DNA-PK with the Drug Agonist AsiDNA
por: Berthault, Nathalie, et al.
Publicado: (2022)